We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Acetylated Tubulin Is a Biomarker for Severe Depression

By LabMedica International staff writers
Posted on 23 Apr 2020
A recent study suggested that the structural protein tubulin could serve as a novel diagnostic biomarker for severe depression.

The molecular mechanisms involved in the development of depression, which in its severest form may lead to suicide, are only poorly understood. More...
It is known that post-translational modifications of the structural protein tubulin alter microtubule dynamics and play a role in mood disorders. Furthermore, tubulin interacts closely with G-alpha-s, the G-protein responsible for activation of adenylyl cyclase. This enzyme catalyzes the production of cAMP, a molecule necessary for quick messaging in the brain.

Investigators at the University of Illinois at Chicago (USA) examined the amount of modified (acetylated) tubulin present in the brains from people who were not depressed as well as those from people with depression who died by suicide or by other causes.

For this study, the investigators evaluated tubulin acetylation in whole tissue homogenates and in plasma-membrane and lipid-raft membrane domains in tissue from normal control (NC) subjects, depressed suicides, and depressed non-suicides (human males/females). Lipid rafts are areas within the plasma membranes of cells, which contain combinations of glycosphingolipids, cholesterol, and protein receptors organized into glycolipoprotein lipid microdomains.

Results sited in the current study tissue indicated that tissue homogenates showed no changes in tubulin acetylation between controls, depressed suicides, and depressed non-suicides. However, plasma-membrane associated tubulin showed significant decreases in acetylation from depressed-suicides and depressed-non-suicides compared to controls. No change was seen in expression of the enzymes responsible for tubulin acetylation or de-acetylation.

The investigators said that these results suggested that during depression, tubulin localized in the membrane maintained a lower acetylation state, permitting increased sequestration of G-alpha-s in lipid-raft domains, where it was less likely to couple to adenylyl cyclase for cAMP production. Imaging studies have shown that depressed individuals have less cAMP in their brains, which is remedied by successful treatment.

The study was published in the April 13, 2020, online edition of the Journal of Neuroscience.

Related Links:
University of Illinois at Chicago


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.